WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60

Login

Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :

Download Article: Click Here

Search

Track Your Article

Abstract

ROLE OF AZOLE ANTIFUNGAL AGENTS IN SEBORRHEIC DERMATITIS & DANDRUFF: A REVIEW

A. Rajendiran?, Sudheer Rawat, Anju Singh, Amana Parveen and Subham Goutham

Abstract

Seborrheic Dermatitis (SD) also known as Dandruff which affects the Seborrheic area of the body (Skin and cavities). In this review, summarize the current knowledge including chemistry, pathophysiology, and treatment with azole antifungal agents. Azole antifungal agents are currently used in various fungal infections mainly as topical preparation such as cream, ointment, shampoo, gel, etc. most clinically useful drugs are Ketoconazole, Miconazole, Metronidazole, Itraconazole, Bifonazole Most imidazole derivatives are suitable for topically used because of their poor absorption and tolerable in systemically (Clotrimazole, Oxiconazole, Econazole, Isoconazole, Bifonazole, etc.). Miconazole can be given systemically or locally, Ketoconazole orally active because of better absorption Fluconazole and Itraconazole are newer orally effective triazole derivatives. Imidazole derivatives act as fungistatic (stop fungal growth) or fungicidal (destroy the fungus), they act by inhibiting sterol (ergosterol) synthesis, as it is an integral part of the cytoplasmic cell membrane of fungi.

Keywords: Azole, Dandruff, Imidazole Antifungal drugs, Seborrheic Dermatitis.


[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More